Status:
RECRUITING
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age ≥18
- Untreated clinical stage I NSCLC amenable to upfront surgery
- Untreated stage II to IIIB NSCLC amenable to neoadjuvant treatment followed by surgery
- ECOG Performance Status of ≤2 Of note, the E-nose is a completely noninvasive technology (only breath samples are collected). Therefore, this intervention would have no effects on a developing human fetus. There are therefore no requirements for the study population related to contraception or pregnancy testing.
Exclusion
Key Trial Info
Start Date :
October 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07218601
Start Date
October 10 2025
End Date
October 1 2027
Last Update
December 23 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
2
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States, 07748
3
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States, 07645
4
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
Commack, New York, United States, 11725